Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pseudohypoparathyroidism.

Agnès Linglart1, Michael A Levine2, Harald Jüppner3

  • 1INSERM-U1185, Paris Sud Paris-Saclay University, Bicêtre Paris Sud Hospital, 64 Gabriel Péri Street, 94270 Le Kremlin Bicêtre, France; APHP, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Network OSCAR and 'Platform of Expertise Paris Sud for Rare Diseases, Bicêtre Paris Sud Hospital, 64 Gabriel Péri Street, 94270 Le Kremlin Bicêtre, France; APHP, Endocrinology and Diabetes for Children, Bicêtre Paris Sud Hospital, 64 Gabriel Péri Street, 94270 Le Kremlin Bicêtre, France.

Endocrinology and Metabolism Clinics of North America
|November 5, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal position of a GNAS methylation regulatory element causes autosomal dominant pseudohypoparathyroidism type 1B (PHP1B).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.

Journal of the Endocrine Society·2026
Same author

Continuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment.

European journal of endocrinology·2026
Same author

Excluding children: What "no-kids zones" reveal about our collective future.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study.

The lancet. Diabetes & endocrinology·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026

Pseudohypoparathyroidism (PHP) is a group of rare metabolic disorders affecting hormone signaling. Research through patient registries is crucial for understanding PHP mechanisms and developing new treatments.

Area of Science:

  • Endocrinology
  • Genetics
  • Metabolic Disorders

Background:

  • Pseudohypoparathyroidism (PHP) involves impaired Gsα/cAMP/PKA signaling, affecting hormone response.
  • Characterized by PTH resistance, leading to hypocalcemia and hyperphosphatemia.
  • Commonly presents with brachydactyly, ectopic ossification, obesity, or short stature.

Purpose of the Study:

  • Highlight the need for patient registries and large cohorts in PHP research.
  • Emphasize improving knowledge of underlying disease mechanisms.
  • Facilitate the development of novel therapeutic strategies for PHP.

Main Methods:

  • Review of existing literature on Pseudohypoparathyroidism.
  • Analysis of clinical and genetic data from patient cohorts (implied).
Keywords:
AcrodysostosisBrachydactylyEarly-onset obesityGNASPTH resistancePseudohypoparathyroidismSubcutaneous ossifications

Related Experiment Videos

  • Identification of research gaps and therapeutic needs.

    • Main Results:

    • PHP is a heterogeneous disorder impacting hormone signaling pathways.
    • Clinical manifestations are diverse, including skeletal and metabolic abnormalities.
    • Current knowledge of PHP pathogenesis and treatment is limited.

    Conclusions:

    • Establishing patient registries is essential for advancing PHP research.
    • Further research is required to elucidate PHP disease mechanisms.
    • Development of targeted therapies for Pseudohypoparathyroidism is a key goal.